"QuantityPath","Parameter","PKParameter","Value"
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Lipophilicity","C_max",-0.236586420012246
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Specific intestinal permeability (transcellular)","C_max",0.230561893546417
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A9-Kassahun 2007-In vitro Vmax for liver microsomes","C_max",-0.0803178312473734
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A1-Kassahun 2007-In vitro Vmax for liver microsomes","C_max",-0.191110766903591
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Iwamoto 2008 400mg PO (Figure 1) omeprazole study-Weibull (granules)-Dissolution shape","C_max",0.956025503317763
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Lipophilicity","t_max",0
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Specific intestinal permeability (transcellular)","t_max",-0.392857142857143
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A9-Kassahun 2007-In vitro Vmax for liver microsomes","t_max",0
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A1-Kassahun 2007-In vitro Vmax for liver microsomes","t_max",0
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Iwamoto 2008 400mg PO (Figure 1) omeprazole study-Weibull (granules)-Dissolution shape","t_max",0
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Lipophilicity","C_tEnd",-0.692434302310659
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Specific intestinal permeability (transcellular)","C_tEnd",-0.222386492989737
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A9-Kassahun 2007-In vitro Vmax for liver microsomes","C_tEnd",-0.35246529638867
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A1-Kassahun 2007-In vitro Vmax for liver microsomes","C_tEnd",-0.485239550104345
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Iwamoto 2008 400mg PO (Figure 1) omeprazole study-Weibull (granules)-Dissolution shape","C_tEnd",0.0406106874902331
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Lipophilicity","AUC_tEnd",-0.38353783546944
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Specific intestinal permeability (transcellular)","AUC_tEnd",0.0778322350142917
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A9-Kassahun 2007-In vitro Vmax for liver microsomes","AUC_tEnd",-0.257378022879449
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A1-Kassahun 2007-In vitro Vmax for liver microsomes","AUC_tEnd",-0.414490045262715
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Iwamoto 2008 400mg PO (Figure 1) omeprazole study-Weibull (granules)-Dissolution shape","AUC_tEnd",0.852358008124847
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Lipophilicity","AUC_inf",-0.385616407903436
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Specific intestinal permeability (transcellular)","AUC_inf",0.0724001370223692
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A9-Kassahun 2007-In vitro Vmax for liver microsomes","AUC_inf",-0.258490265436754
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A1-Kassahun 2007-In vitro Vmax for liver microsomes","AUC_inf",-0.414549110766283
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Iwamoto 2008 400mg PO (Figure 1) omeprazole study-Weibull (granules)-Dissolution shape","AUC_inf",0.82443136607869
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Lipophilicity","MRT",-0.100165071679082
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Specific intestinal permeability (transcellular)","MRT",-0.166186611112049
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A9-Kassahun 2007-In vitro Vmax for liver microsomes","MRT",-0.103083880931294
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A1-Kassahun 2007-In vitro Vmax for liver microsomes","MRT",-0.108293707717204
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Iwamoto 2008 400mg PO (Figure 1) omeprazole study-Weibull (granules)-Dissolution shape","MRT",-0.386342941339412
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Lipophilicity","Thalf",0.227627283374097
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Specific intestinal permeability (transcellular)","Thalf",0.0849831963267088
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A9-Kassahun 2007-In vitro Vmax for liver microsomes","Thalf",0.0511000729882483
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A1-Kassahun 2007-In vitro Vmax for liver microsomes","Thalf",0.0682436472009968
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Iwamoto 2008 400mg PO (Figure 1) omeprazole study-Weibull (granules)-Dissolution shape","Thalf",-0.294615312450828
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Lipophilicity","FractionAucLastToInf",-0.0788757649708089
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Specific intestinal permeability (transcellular)","FractionAucLastToInf",-0.209434642431461
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A9-Kassahun 2007-In vitro Vmax for liver microsomes","FractionAucLastToInf",-0.0428323645200214
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A1-Kassahun 2007-In vitro Vmax for liver microsomes","FractionAucLastToInf",-0.0022180987403218
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Iwamoto 2008 400mg PO (Figure 1) omeprazole study-Weibull (granules)-Dissolution shape","FractionAucLastToInf",-1.07343244857514
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Lipophilicity","CL",0.385629443372843
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Specific intestinal permeability (transcellular)","CL",-0.0724435780980806
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A9-Kassahun 2007-In vitro Vmax for liver microsomes","CL",0.25851813779855
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A1-Kassahun 2007-In vitro Vmax for liver microsomes","CL",0.414269728275604
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Iwamoto 2008 400mg PO (Figure 1) omeprazole study-Weibull (granules)-Dissolution shape","CL",-0.829141875723871
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Lipophilicity","Vss",0.285692619608565
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Specific intestinal permeability (transcellular)","Vss",-0.238760343451033
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A9-Kassahun 2007-In vitro Vmax for liver microsomes","Vss",0.155418942303268
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A1-Kassahun 2007-In vitro Vmax for liver microsomes","Vss",0.306072362244589
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Iwamoto 2008 400mg PO (Figure 1) omeprazole study-Weibull (granules)-Dissolution shape","Vss",-1.21595044991802
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Lipophilicity","Vd",0.614169993688683
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Specific intestinal permeability (transcellular)","Vd",0.0126690533765543
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A9-Kassahun 2007-In vitro Vmax for liver microsomes","Vd",0.309618847427953
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A1-Kassahun 2007-In vitro Vmax for liver microsomes","Vd",0.482450778190098
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Iwamoto 2008 400mg PO (Figure 1) omeprazole study-Weibull (granules)-Dissolution shape","Vd",-1.12371088932093
